STOK

Stoke Therapeutics, Inc. (STOK) | Rumor.io

Stoke Therapeutics

STOK

Attention (50-day avg)0%

Attention rank (50-day avg)#2,318

Bullish sentiment (50-day avg)50%

Price to earnings ratio48.8

Market capitalization1.6B

Earnings per share-3.39

Dividend yield (TTM)—

Revenue (annual)184.4M

Net income (annual)-6.9M

Social

What share of all stock conversation is about STOK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0.01% +0.01

May 12

Stoke Therapeutics, Inc. (STOK) has a new product update for Hay Day, with a 2x Kamyon event and new kuzu products.
A store is offering a promo for STOK products, with discounts on speakers, amplifiers, and home theaters.
Lang Motor Sidoarjo has a ready stock of STOK products available for purchase, with various payment options and services.

Generated by AI

Sentiment

Of the messages about STOK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0%	40% -26.67	90.19% +14.3
Bearish	—	100%	60% +26.67	9.81% -14.3

Bullish· Mar 28

Stoke Therapeutics, Inc. ($STOK) has seen strong demand for its stock, with an upsized equity offering of $125M at $13.50 per share, indicating a positive market sentiment.
The company's recent positive Phase 1 data has led to a significant price increase, with $STOK trading as high as $16+ and showing a 216.43% gain since the Magic signal was triggered.
Institutional ownership of $STOK is above 97%, and the stock has a low price of $17 with an average of $23, indicating potential for further price appreciation.

Bearish· Mar 27

$STOK is due for a reversal after a failed gap up, potentially forming a "hanging tampon" setup.
The company's upcoming offering is expected to be dilutive, potentially adding 20-25% more shares to the float at a price around $9-10.
A short squeeze in $STOK is unlikely to hold, with many traders expecting a reversal or a slow fade back down.

Generated by AI

Topics

Of the messages about STOK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	11.11%	50%	76%
Analysts	—	72.22%	40.63%	3.11%
Technical Analysis	—	16.67%	9.38%	18.89%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	2%
Macro	—	0%	0%	0%

Announcements· Feb 18

Biogen has partnered with Stoke Therapeutics to develop and commercialize Zorevunersen for the treatment of Dravet Syndrome, a rare genetic epilepsy.
Stoke Therapeutics will receive a $165M upfront payment and may earn up to $385M in additional milestones from the collaboration.
A global Phase 3 trial for Zorevunersen is set to begin in Q2 2025, with Biogen taking global rights to the treatment in the deal.

Technical Analysis· Mar 27

$STOK has shown a 2-2 reversal, indicating a potential trend reversal, and has also exhibited a clean scalping opportunity.
The stock has formed a "hanging tampon" setup, characterized by a failed gap up, which may lead to a reversal in the following day.
$STOK has been identified as a potential candidate for a multi-halter gap move, with a possible break above a key resistance level, and may be setting up for a big price move.

Generated by AI

Community

Of the messages about STOK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	35.71%	6.97%
Newcomers	100%	100%	64.29%	93.03%

Regulars· Mar 26

The positive data from the STK-001 DS program exceeded investor expectations, showing robust and consistent seizure reduction.
The company is on track to initiate a registrational study for its Dravet syndrome drug after the encouraging results.
Stoke Therapeutics plans to move forward with a proposed public offering, potentially raising funds to support its ongoing programs.

Newcomers· May 11

Newcomers are discussing the upcoming event on Monday, November 5, 2026, and its potential impact on the stock.
Some users are sharing news articles about Stoke Therapeutics' research and development efforts, highlighting the company's focus on gene therapy.
Others are speculating about the stock's price movement in response to the event, with some anticipating a potential surge.

Generated by AI

BEDFORD, Mass., September 16, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on September 15, 2026, it granted stock options to purchase an aggregate of 53,175 shares of common stock to

14d agoYahoo Finance

Goldman Sachs reiterates Stoke Therapeutics stock rating on Dravet study confidence

20d agoInvesting.com

Stoke Therapeutics at Cantor conference: dravet data, cash runway

20d agoInvesting.com

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

–4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on top of standard of care anti-seizure medicines– –New data showed substantial reductions in the most severe seizure types, the leading risk factor for sudden unexpected death in epilepsy (SUDEP)– –Improvements in quality of life were demonstrated through 28 months of treatment– –Zore

26d agoYahoo Finance

Stoke Therapeutics to Present at the Cantor Global Healthcare Conference

BEDFORD, Mass., September 02, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Cantor Global Healthcare

27d agoYahoo Finance

Also Discussed

Investors talking about STOK also mention

#	Name	Attention
1	NBSE - NeuBase Therapeutics, Inc.	——
2	Alector Inc.ALEC	0%new
3	AnaptysBio, Inc.ANAB	0%0
4	SWTX - SpringWorks Therapeutics, Inc.	——
5	Praxis Precision Medicines, Inc.PRAX	0%0
6	Estrella Immunopharma, Inc.ESLA	0%0
7	Bicycle Therapeutics plc - ADRBCYC	0%0
8	SLNO - Soleno Therapeutics, Inc.	——
9	VERV - Verve Therapeutics, Inc.	——
10	Madrigal Pharmaceuticals Inc.MDGL	0%-0.02

Stoke Therapeutics, Inc.

Healthcare
Biotechnology

Stoke Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing RNA-based medicines for severe genetic diseases. Its programs are designed to upregulate protein expression and address the underlying cause of disorders linked to insufficient protein production. The company’s portfolio centers on precision therapies for rare neuromuscular, neurological, and other haploinsufficiency-related conditions, with a strong emphasis on antisense oligonucleotide approaches and targeted gene output modulation. Stoke Therapeutics operates in the genetic medicines and rare disease markets, where its research platform supports the discovery and development of treatments intended to restore healthier levels of naturally occurring proteins. Headquartered in Bedford, Massachusetts, Stoke Therapeutics plays a specialized role in advancing novel therapeutic approaches for patients with complex inherited diseases.

Website

Location

45 Wiggins Avenue

Bedford, MA, 01730

United States

Social

What share of all stock conversation is about STOK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0.01% +0.01

May 12

Stoke Therapeutics, Inc. (STOK) has a new product update for Hay Day, with a 2x Kamyon event and new kuzu products.
A store is offering a promo for STOK products, with discounts on speakers, amplifiers, and home theaters.
Lang Motor Sidoarjo has a ready stock of STOK products available for purchase, with various payment options and services.

Generated by AI

Sentiment

Of the messages about STOK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0%	40% -26.67	90.19% +14.3
Bearish	—	100%	60% +26.67	9.81% -14.3

Bullish· Mar 28

Stoke Therapeutics, Inc. ($STOK) has seen strong demand for its stock, with an upsized equity offering of $125M at $13.50 per share, indicating a positive market sentiment.
The company's recent positive Phase 1 data has led to a significant price increase, with $STOK trading as high as $16+ and showing a 216.43% gain since the Magic signal was triggered.
Institutional ownership of $STOK is above 97%, and the stock has a low price of $17 with an average of $23, indicating potential for further price appreciation.

Bearish· Mar 27

$STOK is due for a reversal after a failed gap up, potentially forming a "hanging tampon" setup.
The company's upcoming offering is expected to be dilutive, potentially adding 20-25% more shares to the float at a price around $9-10.
A short squeeze in $STOK is unlikely to hold, with many traders expecting a reversal or a slow fade back down.

Generated by AI

Topics

Of the messages about STOK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	11.11%	50%	76%
Analysts	—	72.22%	40.63%	3.11%
Technical Analysis	—	16.67%	9.38%	18.89%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	2%
Macro	—	0%	0%	0%

Announcements· Feb 18

Biogen has partnered with Stoke Therapeutics to develop and commercialize Zorevunersen for the treatment of Dravet Syndrome, a rare genetic epilepsy.
Stoke Therapeutics will receive a $165M upfront payment and may earn up to $385M in additional milestones from the collaboration.
A global Phase 3 trial for Zorevunersen is set to begin in Q2 2025, with Biogen taking global rights to the treatment in the deal.

Technical Analysis· Mar 27

$STOK has shown a 2-2 reversal, indicating a potential trend reversal, and has also exhibited a clean scalping opportunity.
The stock has formed a "hanging tampon" setup, characterized by a failed gap up, which may lead to a reversal in the following day.
$STOK has been identified as a potential candidate for a multi-halter gap move, with a possible break above a key resistance level, and may be setting up for a big price move.

Generated by AI

Community

Of the messages about STOK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	35.71%	6.97%
Newcomers	100%	100%	64.29%	93.03%

Regulars· Mar 26

The positive data from the STK-001 DS program exceeded investor expectations, showing robust and consistent seizure reduction.
The company is on track to initiate a registrational study for its Dravet syndrome drug after the encouraging results.
Stoke Therapeutics plans to move forward with a proposed public offering, potentially raising funds to support its ongoing programs.

Newcomers· May 11

Newcomers are discussing the upcoming event on Monday, November 5, 2026, and its potential impact on the stock.
Some users are sharing news articles about Stoke Therapeutics' research and development efforts, highlighting the company's focus on gene therapy.
Others are speculating about the stock's price movement in response to the event, with some anticipating a potential surge.

Generated by AI

Stoke Therapeutics

Social

May 12

Bullish· Mar 28

Bearish· Mar 27

Announcements· Feb 18

Technical Analysis· Mar 27

Regulars· Mar 26

Newcomers· May 11

Stoke Therapeutics appoints Bo Cumbo to board of directors

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Goldman Sachs reiterates Stoke Therapeutics stock rating on Dravet study confidence

Stoke Therapeutics at Cantor conference: dravet data, cash runway

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Stoke Therapeutics to Present at the Cantor Global Healthcare Conference

Also Discussed

Stoke Therapeutics, Inc.

Company Information

Location

Stoke Therapeutics appoints Bo Cumbo to board of directors

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Goldman Sachs reiterates Stoke Therapeutics stock rating on Dravet study confidence

Stoke Therapeutics at Cantor conference: dravet data, cash runway

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Stoke Therapeutics to Present at the Cantor Global Healthcare Conference

Also Discussed

Social

May 12

Bullish· Mar 28

Bearish· Mar 27

Announcements· Feb 18

Technical Analysis· Mar 27

Regulars· Mar 26

Newcomers· May 11